TRCT
AEGR

Tower Research Capital (TRC)’s Aegerion Pharmaceuticals AEGR Stock Holding History

Tower Research Capital (TRC)’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-9,359
Closed -$14K – 5155
2016
Q2 		$14K Buy
9,359
+5,469
+141% +$12.5K ﹤0.01% 2564
2016
Q1 		$15K Buy
3,890
+2,888
+288% +$17.9K ﹤0.01% 1593
2015
Q4 		$10K Buy
+1,002
New +$12.1K ﹤0.01% 2205
2015
Q3 		– Sell
-1,580
Closed -$30K – 5347
2015
Q2 		$30K Sell
1,580
-898
-36% -$19.4K ﹤0.01% 1781
2015
Q1 		$65K Buy
2,478
+2,059
+491% +$52.4K 0.01% 1262
2014
Q4 		$9K Buy
419
+294
+235% +$7.41K ﹤0.01% 2295
2014
Q3 		$4K Buy
+125
New +$3.88K ﹤0.01% 3527
2014
Q1 		– Sell
-560
Closed -$40K – 5295
2013
Q4 		$40K Sell
560
-687
-55% -$52.5K 0.01% 1596
2013
Q3 		$107K Sell
1,247
-24
-2% -$2.03K 0.01% 1231
2013
Q2 		$81K Buy
+1,271
New +$67.5K 0.01% 621

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Tower Research Capital (TRC)'s AEGR Position: Q3 2016 in Review

Tower Research Capital (TRC) sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2016, closing a stake of 9,359 shares — an estimated $14K sold.

Tower Research Capital (TRC) first reported a position in AEGR in Q2 2013 and held it in 10 quarters. The position peaked at $107K in Q3 2013. 58 funds tracked by Wall St. Rank hold AEGR as of Q3 2016.

  • Tower Research Capital (TRC) reported no remaining Aegerion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9,359 Aegerion Pharmaceuticals shares in Q3 2016, an estimated $14K.
  • Tower Research Capital (TRC) first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Aegerion Pharmaceuticals position peaked at $107K in Q3 2013.
  • 58 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2016, filed 8 Nov 2016.